Two people can buy supplements that each say “500 mg ashwagandha root extract” yet receive materially different preparations. The number states ingredient mass, not extraction ratio, constituent profile, analytical method, or clinical equivalence. Individual response, adherence, dose, and expectations also matter. In the United States, a Supplement Facts panel generally declares the botanical ingredient and its amount; it does not automatically provide a full chromatographic profile of individual withanolides. Reading “500 mg” as a measure of potency can therefore be misleading.

What “Ashwagandha Extract” Can Actually Mean

Withania somnifera (L.) Dunal belongs to the Solanaceae family. Its roots and leaves contain steroidal lactones known as withanolides, together with alkaloids and other constituents. Root and leaf chemistry are not identical, and modern supplements may contain root alone or combinations of root and leaf. Withanolides are widely used as analytical markers, but no single compound has been established as the sole source of the botanical’s clinical effects. Plant part, solvent, drug-to-extract ratio, and assay help define an “extract.”

The Ayurvedic Pharmacopoeial Identity

The Ayurvedic Pharmacopoeia of India identifies Aśvagandhā as the dried mature root of Withania somnifera. Its monograph lists tikta and kaṣāya rasa, laghu guṇa, uṣṇa vīrya, madhura vipāka, and the actions rasāyana, balya, vājīkaraṇa, and vātakaphāpaha. It also specifies not less than 0.2% total alkaloids and gives 3–6 g as the dose of the powdered drug. These standards describe root powder and should not be converted directly into a concentrated-extract dose. The API also publishes a separate monograph for Aśvagandhā water extract, confirming that extract and root powder are distinct materials.

What Standardization Does—and Does Not—Tell You

Pharmacopoeial standards illustrate why the assay must be named. The United States Pharmacopeia defines ashwagandha root and root powder as containing not less than 0.3% withanolides, calculated as a specified sum of aglycones and glycosides. Its root dry-extract monograph sets a higher minimum of 2.5% and permits extraction with methanol, alcohol, water, or their mixtures. A “5% withanolides” declaration should be read with its test method and specification. It does not inherently mean “5% withaferin A”: withaferin A is one individual withanolide, whereas “total withanolides” may refer to a defined group measured by a particular method.

KSM-66 and Sensoril Are Not Interchangeable Extracts

Branded extracts make the distinction clearer. KSM-66 is marketed as a root-only extract standardized to at least 5% withanolides; a randomized trial identified by PMID 23439798 used 300 mg twice daily of a high-concentration full-spectrum root extract in adults with chronic stress. Sensoril is a water-based root-and-leaf extract whose manufacturer specifies at least 10% withanolide glycosides, at least 32% oligosaccharides, and no more than 0.5% withaferin A. Trials evaluate the exact preparations, doses, and durations used. Their results cannot be transferred automatically to a generic powder or to another extract merely because the milligram amount is similar.

How Processing Changes the Finished Material

Extraction concentrates selected soluble constituents and leaves others behind. Solvent, temperature, plant part, and drug-to-extract ratio can change the composition. Even a “total withanolides” value does not fully describe the relative amounts of individual withanolides or their absorption. A pharmacokinetic comparison of four extracts given at equivalent total-withanolide doses found different plasma-exposure profiles, illustrating that equal marker totals do not guarantee bioequivalence.

A 2025 analytical study examined 19 extract products and five root-powder products. The measured combined withanolide and withanoside values departed from label-specified percentages by factors of about 2 to 35 in the products assessed. The root powders were around 0.2–0.3% for the measured combined compounds. This supports checking the identity, assay method, specification, and batch result rather than using a universal “250-fold” rule.

Comparison of Common Ashwagandha Materials

These categories are quality-control descriptions, not dose equivalents; percentages from different methods are not necessarily comparable.

Material Plant Part Declared or Compendial Standard Practical Meaning
API Aśvagandhā Dried mature root Not less than 0.2% total alkaloids Classical single-drug identity; powder dose listed separately
USP root or root powder Dried mature root Not less than 0.3% specified total withanolides Compendial raw-root standard
USP root dry extract Root Not less than 2.5% specified total withanolides Concentrated material defined by its own monograph
KSM-66 Root only Manufacturer specification: at least 5% withanolides Apply KSM-66 trial findings only to the studied preparation
Sensoril Root and leaf Manufacturer specification: at least 10% withanolide glycosides; withaferin A no more than 0.5% Chemically and traditionally distinct from the API root drug
Generic extract Must be stated or verified Depends on label, method, and certificate of analysis Milligrams alone do not establish equivalence
WHY ASHWAGANDHA PRODUCTS DIFFER: THE QUALITY CHAIN
Botanical Identity and Plant Part
Confirm Withania somnifera and whether the material is root, leaf, or both.
Extraction and Concentration
Record the solvent and drug-to-extract ratio rather than relying on capsule weight alone.
Assay Definition
Identify which compounds are included, the percentage specification, and the analytical method.
Batch Verification
Look for lot-specific testing for identity, strength, microbes, heavy metals, and relevant contaminants.

Implications for Clinical Interpretation

A trial result belongs first to the preparation that was tested. Reviews of ashwagandha for stress and sleep include root extracts, root-and-leaf extracts, root granules, differing marker concentrations, and widely differing doses. A result for one proprietary extract does not establish how every product labeled “ashwagandha” will perform. Product identity, dose, duration, participant population, and outcome measure should be examined together.

Safety and Choosing a Product

Standardization improves reproducibility but does not make ashwagandha risk-free. Short-term use for up to about three months has generally been well tolerated in trials, while long-term safety remains uncertain. Possible adverse effects include stomach upset, loose stools, nausea, and drowsiness. Rare cases of clinically apparent liver injury have been reported; the mechanism is unclear, and case reports do not establish that leaf material or withaferin A was the common cause. People with cirrhosis or advanced chronic liver disease should avoid it. Ashwagandha can also affect thyroid function and may interact with sedatives, immunosuppressants, diabetes medicines, blood-pressure medicines, and thyroid medicines.

Choose a product that states the plant part, extract ratio or concentration, marker definition, assay method, and lot number. A certificate of analysis should match the batch and include identity, potency, microbial, and heavy-metal testing. USP Verified or NSF certification can add independent checks on label accuracy, contaminants, and manufacturing quality, although certification does not prove that a supplement will produce a specific clinical outcome. Pregnant or breastfeeding people, children, people with thyroid, autoimmune, liver, or hormone-sensitive conditions, and those taking medication should consult a qualified Ayurvedic practitioner and healthcare provider before use. Stop the product and seek medical care for jaundice, dark urine, severe itching, persistent vomiting, or marked abdominal pain.

Ashwagandha quality is best judged by a chain of evidence rather than a single front-label number. The closest match to a clinical study is a product with the same plant part, extraction type, marker specification, dose, and duration. For traditional Ayurvedic use, the API root identity and individualized professional assessment remain the appropriate reference points.

References

  1. FDA
  2. NIH Office of Dietary Supplements
  3. Ayurvedic Pharmacopoeia of India
  4. Ayurvedic Pharmacopoeia of India
  5. Ayurvedic Pharmacopoeia of India
  6. Doi (doi.usp.org)
  7. Doi (doi.usp.org)
  8. Ksm66ashwagandhaa (ksm66ashwagandhaa.com)
  9. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed
  10. Eu-assets (eu-assets.contentstack.com)
  11. Randomized, Double-Blind, Crossover Study Comparing the Bioavailability of 4 Ashwagandha (Withania somnifera (L.) Dunal) Extracts in Healthy Adults Under Fasting Condition (2025), PubMed Central
  12. Determination of Withanolides and Withanosides in Ashwagandha Based Products Using HPLC‐Drift‐Tube‐Ion‐Mobility Quadrupole Time‐of‐Flight Mass Spectrometry (2025)
  13. NCCIH
  14. NCBI
  15. Usp (usp.org)
  16. Nsf (nsf.org)